Check Out What’s New at Goldfinch
Goldfinch Bio to Present at the Raymond James Human Health Innovation Conference
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)
Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.
Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer